Sign in
PASG Stock Price, Chart, Stats & News
Passage Bio, Inc.
Save
17.93M
Market cap
–
Current P/E
–
Forward P/E
PASG chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -73.09% |
ROE | -135.04% |
D/E | 1.28x |
Interest coverage ratio | – |
PASG valuation
P/E | – |
P/S | – |
P/B | 1.08x |
P/CF | -0.64x |
P/FCF | -0.65x |
P/OCF | -0.64x |
PEG | -3.22x |
EV multiple | -1.06x |
About
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN.
Similar securities
Based on sector and market capitalization
Report issue